News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Daiichi Suntory Pharma Co., Ltd., BioMarin Pharmaceutical Inc. (BMRN) To Enter Into Licensing Agreement For Phenoptin For The Treatment Of PKU


10/19/2005 5:12:19 PM

Daiichi Suntory Pharma and BioMarin Pharmaceutical (Nasdaq and SWX: BMRN) have entered into a strategic business partnership for Phenoptin (sapropterin hydrochloride), an investigational oral enzyme cofactor for the treatment of the genetic disease phenylketonuria (PKU).

Read at JCN Newswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES